Bisoprolol
Bisoprolol, Ziac (bisoprolol) is a small molecule pharmaceutical. Bisoprolol was first approved as Zebeta on 1992-07-31. It is used to treat angina pectoris, heart failure, hypertension, myocardial infarction, and supraventricular tachycardia in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Combinations
Ziac (generic drugs available since 2000-09-25)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bisoprolol | ANDA | 2023-12-07 |
| bisoprolol fumarate | ANDA | 2024-01-09 |
| bisoprolol fumarate and hydrochlorothiazide | ANDA | 2024-02-09 |
| bisoprolol fumarate hydrochlorothiazide | 2006-11-27 | |
| bisoprolol fumarate tablets | ANDA | 2009-09-15 |
| ziac | New Drug Application | 2024-01-04 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AB: Beta blocking agents, selective
— C07AB07: Bisoprolol
— C07B: Beta blocking agents and thiazides
— C07BB: Beta blocking agents, selective, and thiazides
— C07BB07: Bisoprolol and thiazides
— C07F: Beta blocking agents, other combinations
— C07FB: Beta blocking agents and calcium channel blockers
— C07FB07: Bisoprolol and amlodipine
— C07FX: Beta blocking agents, other combinations
— C07FX04: Bisoprolol and acetylsalicylic acid
— C09: Agents acting on the renin-angiotensin system
— C09B: Ace inhibitors, combinations
— C09BX: Ace inhibitors, other combinations in atc
— C09BX02: Perindopril and bisoprolol
— C09BX04: Perindopril, bisoprolol and amlodipine
— C09BX05: Ramipril and bisoprolol
HCPCS
No data
Clinical
Clinical Trials
117 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | 1 | 4 | 4 | 11 | 8 | 25 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | 1 | 12 | 5 | 19 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | 4 | 5 | 10 |
| Coronary artery disease | D003324 | — | I25.1 | 1 | 1 | 1 | 4 | 1 | 7 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | 5 | — | 5 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | 1 | 2 | 1 | 5 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 2 | 1 | 3 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 2 | 1 | — | 3 |
| St elevation myocardial infarction | D000072657 | — | — | — | — | — | 3 | — | 3 |
| Non-st elevated myocardial infarction | D000072658 | — | — | — | — | — | 3 | — | 3 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | 1 | — | — | 3 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 1 | 1 | — | 1 | 2 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | 1 | — | — | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | 1 | — | — | 1 |
| Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | — | 1 | 1 | — | — | 1 |
| Dilated cardiomyopathy | D002311 | HP_0001644 | I42.0 | — | 1 | 1 | — | — | 1 |
| Chagas cardiomyopathy | D002598 | EFO_0005529 | — | — | — | 1 | — | — | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 2 | — | — | 1 | 3 |
| Pheochromocytoma | D010673 | — | — | — | 1 | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | 1 | — | — | — | 1 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | 1 | — | — | — | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Heart rate | D006339 | EFO_0004326 | — | 1 | — | — | — | — | 1 |
| Fasting | D005215 | EFO_0002756 | — | 1 | — | — | — | — | 1 |
| Abdominal aortic aneurysm | D017544 | EFO_0004214 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 2 | 2 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 2 | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | — | 1 | 1 |
| Delirium | D003693 | — | R41.0 | — | — | — | — | 1 | 1 |
| Bradycardia | D001919 | HP_0001662 | R00.1 | — | — | — | — | 1 | 1 |
| Cachexia | D002100 | HP_0004326 | R64 | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | — | 1 | 1 |
| Patient participation | D010358 | — | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bisoprolol |
| INN | bisoprolol |
| Description | Bisoprolol is a secondary alcohol and a secondary amine. It has a role as an antihypertensive agent, a beta-adrenergic antagonist, an anti-arrhythmia drug and a sympatholytic agent. |
| Classification | Small molecule |
| Drug class | beta-blockers (propranolol type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 66722-44-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL645 |
| ChEBI ID | 3127 |
| PubChem CID | 2405 |
| DrugBank | DB00612 |
| UNII ID | Y41JS2NL6U (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Bisoprolol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Bisoprolol
+
Hydrochlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,083 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
24,848 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use